INTRODUCTION
Mucilage is most commonly used as excipients in the manufacturing of different pharmaceutical dosage forms. They have a variety of pharmaceutical properties, which include binding, disintegrating, suspending, emulsifying and sustaining properties at different proportion in different pharmaceutical dosage forms , Mithal et al., 1964 , Mithal et al., 1965 . Natural mucilages are preferred over semi-synthetic and synthetic materials due to their non-toxic, low cost, free availability, emollient and non-irritating nature (Kulkarni et al., 2002 , Washi et al., 1985 . Ispaghula mucilage consists of epidermis of the dried seeds of Plantago ovata.
Fast disintegrating tablet system can be defined as a tablet that disintegrates and dissolves rapidly in saliva within few seconds without need of drinking water (Fu et al., 2004) . In spite of tremendous development in drug delivery technology, oral route remains perfect route for administration of therapeutic reagents because of low cost of therapy, ease of administration, accurate dose, selfmedication, pain avoidance, leading to high level of patient compliance. Tablets and capsules are the most popular dosage forms (Chein et al., 1992) , but main drawback of such dosage forms is dysphasia or difficulty in swallowing. This problem led to development of novel solid dosage forms such as fast disintegrating tablets that disintegrate and dissolve rapidly in saliva without need of water. Fast disintegrating tablets avoid first pass metabolism and enhance bioavailability of active ingredient (Kuchekar et al., 2001) .
Domperidone is widely used antiemetic drug acting by an inhibition of the dopaminergic receptors. Domperidone does not cross blood brain barrier. Domperidone is also effective in gastroparesis, paediatric gastroesophageal reflux (infant vomiting). Domperidone after oral dosing undergoes extensive gastric and hepatic first pass metabolism resulting in low bioavailabality (15%) which therefore, may not minimize the rate of vomiting (Tripathi et al., 2008) . The aim was to formulate fast disintegrating domperidon tablets using Plantago ovata mucilage by 3 2 full factorial design and developing a dosage form with enhanced bioavailability.
MATERIALS AND METHODS
Domperidon was obtained as gift sample from Man Pharmaceuticals Ltd, Mehsana. The seeds of Plantago ovata were purchased from the local market of Ongole, Andhra Pradesh. Directly compressible mannitol (Pearlitol SD200), sodium stearyl fumarate and microcrystalline cellulose (Avicel PH-102) were generous gifts from Strides Arco Labs, Bangalore, Glenmark Ltd., Nashik and Alkem Labs Pvt Ltd, Mumbai, India. All other chemicals used were of analytical reagent grade.
Isolation of mucilage
For the isolation of mucilage (Washi et al., 1985; Bhaveja et al., 1989) seeds of Plantago ovata were used. They were soaked in distilled water for 48 hours and then boiled for 1 hr for complete release of mucilage into water. The material collected was squeezed through muslin cloth for filtering and separating out the marc. Then, an equal volume of acetone was added to the filtrate so as to
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precipitate the mucilage. The separated mucilage was dried (in oven at temperature less than 60°C), powdered, sieved (#60) and stored in a desiccator until further use.
Preparation of fast disintegrating tablets of domperidon
Fast disintegrating tablets of Domperidon were prepared by direct compression method (Shirsand et al., 2009) according to the formulae given in table 1. All the ingredients were passed through #60 mesh separately. The drug and MCC were mixed by taking small portion of both each time and blending it to get a uniform mixture and kept aside. Then the other ingredients were weighed and mixed in geometrical order and tablets were compressed using 6 mm round flat punches to get tablets of 100 mg weight on a 10-station rotary tablet machine (Clit, Ahmedabad).
Evaluation of fast disintegrating tablets
The prepared Fast disintegrating tablets were evaluated for different parameters like hardness, thickness, friability, weight variation test, drug content, wetting time and water absorption ratio, In vitro dispersion time and In vitro dissolution test.
Hardness
The crushing strength of tablets was measured by using Monsanto hardness tester (Devendre et al., 2012) .
Thickness
Tablet thickness was measured by using Screw gauge. Three tablets were randomly taken and measured by placing between two arms of screw gauge.
Weight variation test
Twenty tablets were selected at random and average weight was determined using an electronic balance (Shimadzu BL-220H). Tablets were weighed individually and compared with average weight (Banker et al., 1987) .
Friability test
The friability of tablets was measured in Roche friabilator. 20 tablets were dedusted at 25 rpm for 4 min and weighed again (Lachman et al., 1991) . Percentage friability was calculated from loss in weight as given in equation below. The weight loss should not be more than 1% (table 2) .
Drug content determination
In this test, ten tablets were weighed and powdered. The Domperidon content was determined by measuring the absorbance at 283 nm. The drug content was determined using the standard calibration curve. The mean percent drug content was calculated as an average of three determinations (IP, 1996) .
Wetting time and water absorption ratio
For determination of wetting time and water absorption ratio (Chaudari et al., 2005) , a piece of tissue paper folded twice was placed in a small Petri dish (internal diameter of 5 cm) containing 6 ml of water. A tablet was placed on the paper and the time required for complete wetting was measured. The wetted tablet was then weighed. Water absorption ratio 'R' was calculated using the equation: R=100×(Wa-Wb)/Wa, where Wa is weight of tablet after water absorption and Wb is weight of tablet before water absorption.
In vitro dispersion time
In vitro dispersion time was determined by placing one tablet in a Petri dish containing 10 ml of water and the DF0  DF1  DF2  DF3  DF4  DF5  DF6  DF7  DF8  DF9  C1  C2  Domperidon  10  10  10  10  10  10  10  10  10  10  10  10  Plantago ovataMucilage  -2  2  2  6  6  6  10  10  10  4  8  MCC  10  0  15  30  0  15  30  0  15  30  7.5  22.5  Aspartame  3  3  3  3  3  3  3  3  3  3  3  3  Sodium stearyl fumarate  2  2  2  2  2  2  2  2  2  2  2  2  Talc  2  2  2  2  2  2  2  2  2  2  2  2  Banana flavour  1  1  1  1  1  1  1  1  1  1  1  1  Mannitol SD-200  72  80  65  50  76  61  46  72  67  42  70.5  51.5  Total  100  100  100  100  100  100  100  100  100  100  100  100 Formulation DF9 was selected as the best and used in further studies; DF0 control formulation, C1 and C2 are extra design check-point formulations. time required for complete dispersion was determined (Nilesh et al., 2012; Gohel et al., 2004) .
In vitro dissolution test
In vitro dissolution studies of the optimized fast disintegrating tablets of domperidon and commercial conventional tablet was performed according to USP XXIII Type-II dissolution apparatus (Electrolab, model TDT-06N) employing a paddle stirrer at 50 rpm using 0.1 N HCl at 37±0.5ºC as dissolution medium (Bhagwati et al., 2005) . One tablet was used in each basket. Aliquots of the dissolution medium (5 ml) were withdrawn at specific time intervals (2, 4, 6, 8, 10 and 12 min) and replaced with the equal volume of fresh medium. The samples were analyzed for drug content by measuring the absorbance at 283 nm. Drug concentration was calculated from the standard calibration curve and states cumulative percent drug dissolved.
Drug-excipient interaction study IR spectra of Domperidon and its formulations were obtained by KBr pellet method using Perkin-Elmer FTIR series (Model 1615) spectrophotometer in order to ruled out drug-excipients interactions.
Stability testing
Accelerated stability studies on formulation DF9 were carried out by storing 15 tablets in an amber coloured rubber stoppered vials at 40°C/75% RH over a period of 3 months. At intervals of one month, the tablets were visually examined for any physical changes, changes in drug Content and in vitro dispersion time.
Experimental design
The 3 2 full factorial design was used for the optimization of fast disintegrating tablets of Domperidon (Design Expert 8.0.7.1). The two independent factors, concentration of Plantago ovata mucilage (X1) and concentration of microcrystalline cellulose (X2), were set to three different levels and experimental trials were performed for all nine possible combinations (Boltan et al., 1990) . The dependent response, in-vitro dispersion time (Y1) was evaluated.
Validation of the experimental design
To validate the experimental design using a polynomial equation, the dependent response, in-vitro dispersion time was selected. The following second order polynomial equation was applied as a tool of mathematical modeling (Singh et al., 2008) . Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X1 2 + b22X2 2 where, Y is the dependent variable, b0 is the arithmetic mean response of the nine runs and b1 (b1,b2,,b12,b11 and b22) is the estimated coefficient for corresponding factor X1 (X1,X2,X12,X11,and X22), which represents the average results of changing one factor at a time from its low to high value. The interaction term (X1X2) describes the changes in the response when two factors are simultaneously changed. The polynomial terms (X1 2 and X2 2 ) are included to investigate nonlinearity.
RESULTS AND DISCUSSION
Fast disintegrating tablets of Domperidon were prepared by direct compression method using Plantago ovata mucilage (POM) as natural superdisintigrant and MCC as diluent along with directly compressible mannitol (Pearlitol SD 200), which was used to enhance the mouth feel. A total of nine formulations, a control formulation (DF0, without superdisintegrant) and two extra-design check point formulations (C1 and C2 to check validity of the developed polynomial equation), were designed.
Powder blends were evaluated for the flow parameters such as angle of repose, tapped density, bulk density and Carr's index. The material was free flowing (angle of repose values were found to be less than 30° and Carr's index was less than 15%).
The tablets were evaluated for weight variation, uniformity of drug content, hardness, friability, in vitro dispersion time, in vitro dissolution studies, tablets obtained were of uniform weight (due to uniform die fill), with acceptable variation as per IP specifications (±10%). Drug content was found to be in the range of 95-100%, which is within acceptable limits. Hardness of the tablets was found to be 2.0 to 2.6 kg/cm². Friability below 1% was an indication of good mechanical resistance of the tablets. Formulation DF9 was found to be promising and shown an in vitro dispersion time of 10 sec, which facilitates faster dispersion in the mouth.
In order to investigate the factors systematically, a factorial design was employed in the present investigation. Formulation has been done by using 3² full factorial design, preparing nine batches of formulations (DF1 to DF9). A polynomial equation was derived for in vitro dispersion time, by Design Expert 8.0.7.1 software. Formulation DF9 containing 10% w/w Plantago ovata mucilage, 30% w/w MCC was found to be promising with an in vitro dispersion time of 10 sec against the 175sec displayed by control formulation (DF0), which does not contain the superdisintegrant Plantago ovata mucilage.
In vitro dissolution studies on the promising formulation (DF9), the control (DF0) and conventional commercial tablet formulation (CCF) were carried out in 0.1 N HCl and the various dissolution parameter values, DF0 is control formulation, DF9 is promising fast disintegrating tablet formulation, CCF is conventional commercial tablet formulation, D5 is percent drug released in 5 min, D10 is percent drug release in 10 min, DE10min is dissolution efficiency at 10 min, t25% is time for 25% drug dissolution, t50% is time for 50% drug dissolution, t90% is time for 90% drug dissolution. viz., percent drug dissolved in 5 min (D5), 10 min (D10), dissolution efficiency at 10 min (DE10min), t25%, t50% and t90% are shown in table 3 and the dissolution profile shown in figure 1 . This data reveals that overall, the formulation DF9 has shown nearly four-fold faster drug release (t50% 2.85 min) when compared to CCF (t50% 7.85min). IR studies indicated that the drug is compatible with all the excipients. The IR spectrum of DF9 showed all the characteristic peaks of Domperidon, thus confirming that no interaction of drug with the components of the formulation. Short-term stability studies of the above formulation indicated that there are no significant changes in drug content and in vitro dispersion time at the end of 3 months period (P<0.05).
The 
CONCLUSION
A 3² full factorial design revealed that the amounts of Plantago ovata mucilage (X1) and microcrystalline cellulose (X2) significantly affect the dependent variable (Y1), the in vitro dispersion time. It is thus concluded that, by adopting a systematic formulation approach, an optimum point can be reached in the shortest time with minimum efforts. Direct compression method by using natural superdisintegrants would be an effective approach compared with the use of more expensive excipients in the formulation of fast disintegrating tablets with smaller disintegration time, improved drug dissolution, patient compliance, convenience and acceptability.
